Unique insights from 50 top national and regional Health Plans and 100 Rheumatologists actively prescribing biologics.
The report will cover the latest trial data on new compounds in Rheumatoid Arthritis, Psoriatic Arthritis and Lupus in marketed and late development stage.
For excerpts from the meeting, and for all other inquiries please click here.
Since 2005, Reimbursement Intelligence has helped pharmaceutical, biotech, diagnostic and medical device clients navigate the single most important hurdle to successfully commercializing medical innovation: reimbursement.
When we say reimbursement, we mean the myriad forces of a market in which reimbursement is a central issue for patients, physicians and payers. The successful company, we believe, creates development, launch and marketing strategies based on how all these independent players see and respond to the interconnected issues of access, costs, payments, and medical and personal benefits.
This fundamental belief in a reimbursement ecology dictates our approach to our clients’ challenges. By accepting, understanding and navigating the complexity of reimbursement, we help companies maximize the value of their innovations.
Payers Outlook for Lipitor Generic Strategy Not Rosy: Market Share Decline Coming Soon
Featured in Forbes:“What Managed Care Thinks Of Pfizer And Its Lipitor Strategy”
Payers to Pharma: In Rheumatology, Innovations without Outcomes are Irrelevant
Real Endpoints invests in market research firm Reimbursement Intelligence
PRESS RELEASE: Payers to Pharma: The explosion in use of co-pay cards will raise barriers and patient costs